The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.
The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
The lawsuit alleges Ancestry infringes 23andMe's method of matching relatives and damages its reputation via misleading online marketing.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
KeyGene and its parent firm, KeyGene NV, were named as defendants in a NuGen Technologies suit seeking to invalidate two US patents.
The companies have been embroiled in several lawsuits in the US and in Europe, accusing each other of patent infringement.
The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.
Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.
CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.
In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.